Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm

Heart and Vessels

Volumn 29, Issue 2, 2014, Pages 186-190

  Nishino, Masami ^a   Mori, Naoki ^a   Yoshimura, Takahiro ^a   Nakamura, Daisuke ^a   Lee, Yasuharu ^a   Taniike, Masayuki ^a   Makino, Nobuhiko ^a   Kato, Hiroyasu ^a   Egami, Yasuyuki ^a   Shutta, Ryu ^a   Tanouchi, Jun ^a   Yamada, Yoshio ^a  

^a OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

Endothelial dysfunction; Lipoprotein(a); Uric acid; Vasospasm

Indexed keywords

ACETYLCHOLINE; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; URIC ACID; BIOLOGICAL MARKER; VASOCONSTRICTOR AGENT;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY SPASM; CORONARY RISK; CORONARY VASOSPASTIC ANGINA; ELECTROCARDIOGRAM; FEMALE; HEART FUNCTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROVOCATION TEST; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; THORAX PAIN; URIC ACID BLOOD LEVEL; AGED; ANGINA PECTORIS; BLOOD; CHI SQUARE DISTRIBUTION; COMPLICATION; CORONARY BLOOD VESSEL; CORONARY VASOSPASM; HYPERURICEMIA; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; RISK FACTOR; VASOCONSTRICTION;

ACETYLCHOLINE; AGED; ANGINA PECTORIS; BIOMARKERS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY VASOSPASM; CORONARY VESSELS; FEMALE; HUMANS; HYPERURICEMIA; LIPOPROTEIN(A); MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; URIC ACID; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 84897023239     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-013-0346-x     Document Type: Article

References (40)

1. Yasue H, Horio Y, Nakamura N, Fujii H, Imoto N, Sonoda R, Kugiyama K, Obata K, Morikami Y, Kimura T (1986) Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 74:955-963 (Pubitemid 17174941)
2. Kaski JC, Crea F, Meran D, Rodriguez L, Araujo L, Chierchia S, Davies G, Maseri A (1986) Local coronary supersensitivity to diverse vasoconstrictive stimuli in patients with variant angina. Circulation 74:1255-1265 (Pubitemid 17189245)
3. Yasue H, Takizawa A, Nagao M, Nishida S, Horie M, Kubota J, Omote S, Takaoka K, Okumura K (1988) Long-term prognosis for patients with variant angina and influential factors. Circulation 78:1-9
4. Myerburg RJ, Kessler KM, Mallon SM, Cox MM, deMarchena E, Interian AJ, Castellanos A (1992) Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm. N Engl J Med 326:1451-1455
5. Bory M, Panagides D, Desfossez L (1993) Coronary artery spasm in myocardial infarction. Lancet 342:436 (Pubitemid 23236371)
6. Kugiyama K, Ohgushi M, Motoyama T, Sugiyama S, Ogawa H, Yoshimura M, Inobe Y, Hirashima O, Kawano H, Soejima H, Yasue H (1997) Nitric oxide-mediated flow-dependent dilation is impaired in coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol 30:920-926 (Pubitemid 27435882)
7. Kanellis J, Kang DH (2005) Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 25:39-42 (Pubitemid 40128147)
8. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ (2005) Hyperuricemia induces endothelial dysfunction. Kidney Int 67:1739-1742 (Pubitemid 40577708)
9. Sanchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T, Franco M, Rodriguez-Iturbe B, Johnson RJ (2008) Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Ren Physiol 295:F1134-F1141
10. Tsuchida K, Hori T, Tanabe N, Makiyama Y, Ozawa T, Saigawa T, Watanabe R, Tanaka T, Nasuno A, Fukunaga H, Mezaki T, Nakamura Y, Aizawa Y (2005) Relationship between serum lipoprotein(a) concentrations and coronary vasomotion in coronary spastic angina. Circ J 69:521-525 (Pubitemid 40745723)
11. Tsurumi Y, Nagashima H, Ichikawa K, Sumiyoshi T, Hosoda S (1995) Influence of plasma lipoprotein (a) levels on coronary vasomotor response to acetylcholine. J Am Coll Cardiol 26:1242-1250
12. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Rother J, Wilson PW (2006) International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295:180-189 (Pubitemid 43076437)
13. (2002) New criteria for 'obesity disease' in Japan. Circ J 66:987-992
14. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440-1463 (Pubitemid 41821197)
15. Jcs JWG (2010) Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): digest version. Circ J 74:1745-1762
16. Crea F, Lanza GA (2011) New light on a forgotten disease: vasospastic angina. J Am Coll Cardiol 58:1238-1240
17. Yasue H, Kugiyama K (1997) Coronary spasm: clinical features and pathogenesis. Intern Med 36:760-765 (Pubitemid 128521681)
18. Shimokawa H (2000) Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn Circ J 64:1-12
19. Kugiyama K, Yasue H, Okumura K, Ogawa H, Fujimoto K, Nakao K, Yoshimura M, Motoyama T, Inobe Y, Kawano H (1996) Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 94:266-271
20. Haberland ME, Fless GM, Scanu AM, Fogelman AM (1992) Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 267:4143-4151
21. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330:132-137 (Pubitemid 17158542)
22. Hajjar KA, Gavish D, Breslow JL, Nachman RL (1989) Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339:303-305 (Pubitemid 19130696)
23. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csaszar A, Boerwinkle E, Utermann G (1991) Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 86:607-614
24. Abe A, Noma A (1992) Studies on apolipoprotein(a) phenotypes. Part 1. Phenotype frequencies in a healthy Japanese population. Atherosclerosis 96:1-8
25. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M (2003) Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41:1183-1190 (Pubitemid 36706063)
26. Senmaru T, Fukui M, Tanaka M, Sakabe K, Ushigome E, Asano M, Yamazaki M, Hasegawa G, Nakamura N (2012) N-terminal pro-brain natriuretic peptide could be a marker of subclinical atherosclerosis in patients with type 2 diabetes. Heart Vessels. doi:10.1007/s00380-011-0227-0
27. Mineoka Y, Fukui M, Tanaka M, Tomiyasu K, Akabame S, Nakano K, Yamazaki M, Hasegawa G, Oda Y, Nakamura N (2012) Relationship between cardio-ankle vascular index (CAVI) and coronary artery calcification (CAC) in patients with type 2 diabetes mellitus. Heart Vessels 27:160-165
28. Waring WS, Maxwell SR, Webb DJ (2002) Uric acid concentrations and the mechanisms of cardiovascular disease. Eur Heart J 23:1888-1889 (Pubitemid 35398061)
29. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, Rosano GM (2004) Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 94:932-935 (Pubitemid 39349561)
30. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD (2002) Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106:221-226 (Pubitemid 34761303)
31. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R (2002) Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105:2619-2624 (Pubitemid 34596038)
32. Johnson WD, Kayser KL, Brenowitz JB, Saedi SF (1991) A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J 121:20-24
33. Tabayashi K, Suzuki Y, Nagamine S, Ito Y, Sekino Y, Mohri H (1991) A clinical trial of allopurinol (Zyloric) for myocardial protection. J Thorac Cardiovasc Surg 101:713-718
34. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marban E, Hare JM (2001) Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104:2407-2411 (Pubitemid 33108372)
35. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD (2010) Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 375:2161-2167
36. Rajendra NS, Ireland S, George J, Belch JJ, Lang CC, Struthers AD (2011) Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol 58:820-828
37. Rodrigues TC, Maahs DM, Johnson RJ, Jalal DI, Kinney GL, Rivard C, Rewers M, Snell-Bergeon JK (2010) Serum uric acid predicts progression of subclinical coronary atherosclerosis in individuals without renal disease. Diabetes Care 33:2471-2473
38. Sugiishi M, Takatsu F (1993) Cigarette smoking is a major risk factor for coronary spasm. Circulation 87:76-79 (Pubitemid 23019336)
39. Teragawa H, Kato M, Yamagata T, Matsuura H, Kajiyama G (2000) The preventive effect of magnesium on coronary spasm in patients with vasospastic angina. Chest 118:1690-1695 (Pubitemid 32001797)
40. Yasue H, Mizuno Y, Harada E, Itoh T, Nakagawa H, Nakayama M, Ogawa H, Tayama S, Honda T, Hokimoto S, Ohshima S, Hokamura Y, Kugiyama K, Horie M, Yoshimura M, Harada M, Uemura S, Saito Y (2008) Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol 51:1742-1748 (Pubitemid 351608498)